Good Start Genetics, Inc., an innovative molecular diagnostics company developing the new gold standard in carrier screening, today announced it completed the initial closing of a $14 million Series B Preferred Stock financing, which was led by existing investors OrbiMed Advisors, Safeguard Scientifics, Inc. (NYSE: SFE) and SV Life Sciences. Proceeds from this financing will be used to augment commercial efforts for the Company's pre-conception carrier screening tests, and to support continued R&D efforts around its proprietary technology platform for future applications.

Don Hardison, President and CEO of Good Start Genetics, says, "We are pleased to complete the initial closing of our second financing as it provides the necessary funding to position Good Start Genetics for the next phase of growth. We value the vote of confidence and continued support from our current stockholders and are fortunate to have such a supportive group of world-class investors on our side."

About Good Start Genetics, Inc.
Good Start Genetics is setting the new gold standard in carrier screening by making testing for the most comprehensive set of known and novel disease-causing mutations accessible for routine clinical practice. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable, and affordable tests for all ACOG and ACMG recommended disorders. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results, and no longer have to compromise accuracy for price.
For more information, please visit www.goodstartgenetics.com.

About OrbiMed
OrbiMed is a preeminent investment firm dedicated exclusively to the healthcare sector with over $5 billion in assets under management. OrbiMed invests across the entire spectrum of pharmaceutical, biotechnology and medical device companies on a worldwide basis. Investments are made through venture capital funds, hedge funds, and other investment vehicles. For more information, please visit www.orbimed.com.

About Safeguard Scientifics
Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital and operational support to entrepreneurial and innovative life sciences and technology companies. Specifically in life sciences, Safeguard targets companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine, Specialty Pharmaceuticals and selected healthcare services, and technology companies in Internet / New Media, Financial Services IT, Healthcare IT and selected business services with capital requirements of up to $25 million. For more information, please visit www.safeguard.com.

About SV Life Sciences
SV Life Sciences is a venture capital adviser and manager that make selected investments in businesses with experienced entrepreneurs and management teams. SV Life Sciences provides financing to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology and pharmaceuticals to medical devices and instruments, to healthcare information technology and services. For more information, please visit www.svlsa.com.

This press release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions based on management's current projections and goals and are subject to a number of factors and uncertainties. Information in these forward-looking statements is inherently uncertain and the Company's actual results may differ materially from those anticipated in such forward-looking statements.